Nes-Ziona, Israel, May 24, 2018 – Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that Dr. Bernhard Kirschbaum has joined its board of directors.

Dr. Kirschbaum served as Executive Vice President & Member of the Board at Merck Serono, Head of Global Research & Early Development reporting to the CEO of Merck Serono. He led a global team of  more than 1,200 employees, with a 400 million Euro annual budget. Dr. Kirschbaum has significant expertise in a broad range of disease areas, including rheumatology/immunology, thrombosis, cardio-metabolic diseases, oncology and neurology. He has successfully participated in the profiling of several drugs in their course to the market or during market expansion, including Arava, Velcade, Lovenox, Erbitux and Avelumab. Dr. Kirschbaum led a drug portfolio re-allocation with focus on the therapeutic areas: oncology, neurodegenerative diseases (MS, Alzheimers, Parkinsons), autoimmune and inflammatory Diseases. Dr. Kirschbaum has also been involved in research activities with respect to fertility, mainly focusing on embryo technologies. He implemented the new Merck Serono research organization, including an exploratory medicine department and all non-clinical development functions (toxicology, general & safety pharmacology, CMC development and DMPK). Previously, Dr. Kirschbaum served as Vice President Discovery Research, Global Head of Thrombosis and Angiogenesis at Sanofi-Aventis;  Vice President, Drug Innovation and Approval at  Sanofi-Aventis; and Head of the Center for Applied Genomics (TCAG) at HMR. Dr. Kirschbaum earned his Ph.D. in biochemistry, summa cum laude, from the University of Konstanz, Germany; was a postdoctoral fellow with Dr. R.G. Roeder, at the Rockefeller University in New York, and a Research Associate with Dr. M. Buckingham at Institute Pasteur in Paris.


Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.  For more information, visit


Shachar Shlosberger, CFO

Enlivex Therapeutics, Ltd.